FOXO4-DRI
D-retro-inverso senolytic peptide targeting the FOXO4–p53 interaction
- Class
- Senolytic peptide
- Half-life
- Unknown
- Route
- Subcutaneous (SubQ)
- Cadence
- Cycled (on/off)
- Evidence
- Animal data primarily
Overview
FOXO4-DRI is a senolytic peptide designed to kill senescent cells — the 'zombie cells' that stop dividing but refuse to die and instead pump out inflammatory signals that damage surrounding tissue. It works by disrupting the FOXO4–p53 interaction that keeps senescent cells alive, freeing p53 to trigger apoptosis specifically in these cells while leaving healthy cells alone. The foundational 2017 Cell paper (Baar et al.) showed striking results in aged mice: restored fur density, improved kidney function, better physical performance.
The DRI stands for D-retro-inverso — the peptide is built from mirror-image D-amino acids in reverse sequence, which makes it resistant to the enzymes that would normally break it down in minutes. That structural trick is what allows it to work systemically after injection. The mechanism is elegant: senescent cells rely on FOXO4 to sequester p53 in the nucleus and block apoptosis; FOXO4-DRI outcompetes endogenous FOXO4, p53 relocates to the mitochondria, and the cell dies. Healthy cells don't overexpress FOXO4, so they're unaffected.
The catch: every published study is in mice or cell culture. Zero human trials as of mid-2026. The FOXO4–p53 pathway is conserved in humans, which gives mechanistic plausibility, but the gap between mouse rejuvenation and proven human benefit is real. Senescent cells also play protective roles — wound healing, tumor suppression — so clearing them indiscriminately could backfire. This is a cutting-edge longevity research tool, not a validated therapy.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use anywhere. No regulatory agency has evaluated it. The peptide sold in research markets is unregulated — purity, sterility, and actual sequence fidelity vary wildly between suppliers.
- Zero human safety data. No clinical trials registered as of June 2026. All safety claims extrapolate from mouse studies, where no toxicity was observed at therapeutic doses — but mouse tolerability doesn't guarantee human safety.
- Senescent cells aren't purely harmful — they suppress early-stage tumors and help orchestrate wound healing. Clearing them too aggressively could theoretically impair these protective functions, though this hasn't been documented in animal studies.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching FOXO4-DRI.
- Senescent cell burden (no accessible biomarker yet — blood-based panels in development)
- Physical function markers (grip strength, endurance, gait speed if using for age-related decline)
- Inflammatory markers (CRP, IL-6 — SASP-driven inflammation is what senolytics target)
- Wound healing response (senescent cells aid healing; excessive clearance might impair it)
- Immune function (transient immune stress could theoretically be affected)
Frequently asked questions
What is FOXO4-DRI?
D-retro-inverso senolytic peptide targeting the FOXO4–p53 interaction. FOXO4-DRI is a senolytic peptide designed to kill senescent cells — the 'zombie cells' that stop dividing but refuse to die and instead pump out inflammatory signals that damage surrounding tissue. It works by disrupting the FOXO4–p53 interaction that keeps senescent cells alive, freeing p53 to trigger apoptosis specifically in these cells while leaving healthy cells alone. The foundational 2017 Cell paper (Baar et al.) showed striking results in aged mice: restored fur density, improved kidney function, better physical performance.
How is FOXO4-DRI administered?
Subcutaneous (SubQ), typically cycled (on/off).
What is the half-life of FOXO4-DRI?
Unknown — No human pharmacokinetic data — D-amino acid modification confers protease resistance.
Is FOXO4-DRI approved for human use?
FOXO4-DRI is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for FOXO4-DRI?
Evidence tier: Animal data primarily. Baar et al. 2017 (Cell) dosed naturally aged mice (>24 months) with 5 mg/kg IV every other day for three doses. Results: improved renal function, restored fur density, increased physical performance. Selectivity confirmed — no damage to proliferating tissues, normal blood panels, no weight loss.
What is commonly monitored when researching FOXO4-DRI?
Commonly tracked markers + signals: Senescent cell burden (no accessible biomarker yet — blood-based panels in development), Physical function markers (grip strength, endurance, gait speed if using for age-related decline), Inflammatory markers (CRP, IL-6 — SASP-driven inflammation is what senolytics target), Wound healing response (senescent cells aid healing; excessive clearance might impair it), Immune function (transient immune stress could theoretically be affected).
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.